Imunon, Inc. (identified in this filing as Celsion Corporation) — Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2012; filed November 9, 2012. The filing’s registrant name is Celsion Corporation.
Business context and reporting period
Celsion was a clinical-stage oncology drug developer focused on heat-activated liposomal technology. Its lead candidate, ThermoDox, was being studied in Phase III for primary liver cancer and Phase II for colorectal liver metastases and recurrent chest-wall breast cancer. The company reported no product revenue and expected significant losses while development and commercialization remained ongoing.
Financial results and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 in 2012 and 2011 | $0 in 2012; $2.0 million in 2011 |
| Research and development expense | $3.54 million in 2012; $5.41 million in 2011 | $12.34 million in 2012; $14.73 million in 2011 |
| General and administrative expense | $1.42 million in 2012; $1.41 million in 2011 | $4.59 million in 2012; $3.91 million in 2011 |
| Net loss | $6.02 million in 2012; $6.39 million in 2011 | $18.31 million in 2012; $17.10 million in 2011 |
| Basic and diluted loss per share | $0.18 in 2012; $0.25 in 2011 | $0.55 in 2012; $0.93 in 2011 |
At September 30, cash and cash equivalents were $8.32 million and available-for-sale investments were $14.23 million; together with accrued investment interest, reported liquid resources were approximately $22.7 million. Working capital was $17.2 million, down from $25.3 million at December 31, 2011. Nine-month operating cash use was $16.17 million, and cash and cash equivalents decreased by $11.83 million. No meaningful operating margin is available because the company had no 2012 revenue.
Reported notes payable totaled approximately $5.09 million, including current and non-current portions. Total liabilities were $12.39 million and stockholders’ equity was $13.02 million. The company also reported a $1.42 million common-stock warrant liability.
Material changes versus the prior comparable period
- For the first nine months, operating expenses fell 9.1% to $16.93 million, primarily as R&D declined; however, operating loss increased slightly to $16.93 million from $16.63 million.
- R&D declined 16.2% year over year, mainly because HEAT Study enrollment had reached its target. G&A rose 17.4%, reflecting pre-commercialization analysis, business development and personnel costs.
- 2011 included $2.0 million of Yakult licensing revenue; there was no licensing revenue in 2012. A $1.25 million non-cash warrant revaluation loss in 2012, versus a $42,000 loss in 2011, also affected the year-over-year net loss comparison.
- Cash and investments declined from approximately $30.5 million at year-end 2011 to $22.7 million. The company received $5.0 million under a new secured term loan and approximately $3.9 million gross proceeds from warrant exercises during the third quarter.
Outlook, commentary, risks and unusual items
- Management expected to report top-line HEAT Study results in January 2013. The study had enrolled 700 patients; reaching 380 progression-free-survival events triggered data collection, unblinding and final analysis by the independent Data Monitoring Committee.
- The June 2012 credit agreement provided up to $10 million in two $5 million tranches. The first tranche was funded; the second was conditional on positive Phase III HEAT data and available only through March 31, 2013. The first-tranche rate was 11.75%; substantially all assets other than intellectual property and specified exclusions secured the debt. The company reported compliance with loan covenants.
- Management said additional capital would be needed to develop, manufacture and commercialize its candidates. It warned that financing may not be available on acceptable terms and that insufficient funding could delay, reduce or end programs. No specific cash-runway estimate or financial guidance was provided.
- Hisun was to support ThermoDox manufacturing and China regulatory work; Celsion expected to repay development costs, estimated at approximately $2.0 million, after successful completion of three registration batches. Approximately $95,000 was incurred by September 30. A further Yakult accelerated milestone payment remained conditional on resumption of Japanese HEAT enrollment, which had not occurred.
- After quarter-end, the company reported approximately $681,000 of additional proceeds from warrant and option exercises through the filing date. Clinical, regulatory, manufacturing, financing, competition, reimbursement and intellectual-property risks remain significant. The company reported no legal proceedings and stated disclosure controls were effective at a reasonable-assurance level.
Important facts for investors to verify
- Whether HEAT Study results were released as expected and whether they met the primary endpoint and regulatory requirements.
- Cash use, remaining liquidity and the timing and terms of any additional financing, including availability of the contingent second loan tranche.
- Debt repayment terms, collateral coverage and compliance with credit-agreement covenants.
- Manufacturing-batch progress and the timing and amount of the expected Hisun reimbursement obligation.
- Potential dilution from outstanding warrants, options and future financing; the filing reported 10.17 million warrants outstanding at September 30.